Strs Ohio Tg Therapeutics, Inc. Transaction History

Strs Ohio

$25.5 Billion
Q3 2024

A detailed history of Strs Ohio transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Strs Ohio holds 35,400 shares of TGTX stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,400

Previous 38,000 6.84%

Holding current value

$1.09 Million

Previous $676,000 22.49%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$17.21 - $25.28 $44,746 - $65,728	-2,600 Reduced 6.84%	35,400 $828,000
Q2 2024 Aug 05, 2024	BUY	$13.32 - $19.19 $387,612 - $558,429	29,100 Added 326.97%	38,000 $676,000
Q1 2024 May 13, 2024	SELL	$13.02 - $21.3 $111,972 - $183,180	-8,600 Reduced 49.14%	8,900 $135,000
Q4 2023 Jan 30, 2024	BUY	$6.68 - $18.81 $116,900 - $329,175	17,500 New	17,500 $298,000
Q2 2023 Jul 31, 2023	BUY	$15.48 - $35.0 $123,840 - $280,000	8,000 New	8,000 $198,000
Q2 2022 Jul 25, 2022	BUY	$3.74 - $10.66 $17,952 - $51,168	4,800 Added 21.72%	26,900 $114,000
Q4 2021 Jan 24, 2022	SELL	$15.2 - $35.51 $15,200 - $35,510	-1,000 Reduced 4.33%	22,100 $419,000
Q3 2021 Oct 22, 2021	SELL	$21.78 - $40.45 $67,518 - $125,395	-3,100 Reduced 11.83%	23,100 $768,000
Q2 2021 Jul 26, 2021	SELL	$32.5 - $48.96 $237,250 - $357,408	-7,300 Reduced 21.79%	26,200 $1.02 Million
Q1 2021 Apr 23, 2021	BUY	$41.61 - $54.3 $470,193 - $613,590	11,300 Added 50.9%	33,500 $1.61 Million
Q4 2020 Jan 25, 2021	BUY	$25.27 - $54.9 $166,782 - $362,340	6,600 Added 42.31%	22,200 $1.15 Million
Q3 2020 Dec 14, 2020	BUY	$18.49 - $27.24 $201,540 - $296,916	10,900 Added 231.91%	15,600 $417,000
Q2 2020 Jul 23, 2020	BUY	$8.9 - $21.84 $41,830 - $102,648	4,700 New	4,700 $91,000

Others Institutions Holding TGTX

# of Institutions

335

Shares Held

88.3M

Call Options Held

2.08M

Put Options Held

1.51M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.48B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account